These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21918173)

  • 21. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
    Dignam JJ; Polite BN; Yothers G; Raich P; Colangelo L; O'Connell MJ; Wolmark N
    J Natl Cancer Inst; 2006 Nov; 98(22):1647-54. PubMed ID: 17105987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
    Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
    Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Young age influences treatment but not outcome of colon cancer.
    Quah HM; Joseph R; Schrag D; Shia J; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
    Ann Surg Oncol; 2007 Oct; 14(10):2759-65. PubMed ID: 17593332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
    Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP
    J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
    Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
    Sobrero A; Frassineti G; Falcone A; Dogliotti L; Rosso R; Di Costanzo F; Bruzzi P;
    Br J Cancer; 2005 Jan; 92(1):24-9. PubMed ID: 15611795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.
    Fariña-Sarasqueta A; van Lijnschoten G; Rutten HJ; van den Brule AJ
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1167-71. PubMed ID: 20665215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.
    Ning Y; Gerger A; Zhang W; Hanna DL; Yang D; Winder T; Wakatsuki T; Labonte MJ; Stintzing S; Volz N; Sunakawa Y; Stremitzer S; El-Khoueiry R; Lenz HJ
    Mol Cancer Ther; 2014 Feb; 13(2):528-39. PubMed ID: 24170770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
    Meyerhardt JA; Catalano PJ; Haller DG; Mayer RJ; Benson AB; Macdonald JS; Fuchs CS
    Cancer; 2003 Aug; 98(3):484-95. PubMed ID: 12879464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
    Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of cancer stem cell markers genetic variants with gallbladder cancer susceptibility, prognosis, and survival.
    Yadav A; Gupta A; Rastogi N; Agrawal S; Kumar A; Kumar V; Mittal B
    Tumour Biol; 2016 Feb; 37(2):1835-44. PubMed ID: 26318430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
    J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
    Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological risk factors of Stage II colon cancer: results of a prospective study.
    Santos C; López-Doriga A; Navarro M; Mateo J; Biondo S; Martínez Villacampa M; Soler G; Sanjuan X; Paules MJ; Laquente B; Guinó E; Kreisler E; Frago R; Germà JR; Moreno V; Salazar R
    Colorectal Dis; 2013 Apr; 15(4):414-22. PubMed ID: 22974322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.